Inloggad som:

SGNDV-001/KN-D74

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
Her2
SGNDV-001/KN-D74
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2
PLACEHOLDER
HER2-postiv urinblåsecancer som ska starta 1st line. randomisering mellan Disitamab Vedotin + Pembrolizumab Versus Cytostatika. Central analys av HER2.
Mer information om studien för vårdgivare
Behandling
Fas 3
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2024-11-26)

Tillbaka till listan